Fenwick represented DexCare, a patient demand and
care access platform, in its $75 million Series C financing. The new funding
brings the total raised to $146 million, including two oversubscribed rounds
closed in less than two years. The round was led by ICONIQ Growth with
participation from existing partners Transformation Capital, Kaiser Permanente
Ventures, Define Ventures, Frist Cressey Ventures and SpringRock Ventures.
will advance DexCare’s platform, which extends limited health-system capacity
to serve patients faster and to precisely manage the supply and demand of
digital-care access. More information can be obtained from the company’s
transaction was led by corporate partner Michael Esquivel, counsel Khang Tran
and associate Kasey Wang.